相关临床试验
16
7 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2013
进行中（未招募）
7
43.8%
已完成
4
25.0%
招募中
4
25.0%
终止
1
6.3%
暂无批准数据
- Alzheon will present nine posters on valiltramiprosate at AAIC 2026, featuring expanded Phase 3 APOLLOE4 and Phase 2 trial analyses with new neurovascular protection and DTI imaging evidence. - The Phase 3 trial did not meet its primary endpoint, but pre-specified MCI subgroup analyses showed clinically meaningful cognitive and brain volume benefits alongside lower ARIA rates versus placebo. - Long-term extension data through up to four years demonstrated a favorable safety profile with no symptomatic ARIA-E or ARIA-H observed in APOE4/4 and APOE3/4 carriers. - A QSP analysis will evaluate valiltramiprosate as a potential oral maintenance therapy following plaque clearance with anti-amyloid antibodies such as donanemab or lecanemab.
- Alzheon has dosed the first subject in a Phase 1 clinical trial of ALZ-507, a novel oral drug candidate designed to inhibit neurotoxic soluble amyloid oligomers in Alzheimer's disease. - ALZ-507 features a dual mechanism of action, targeting upstream amyloid aggregation while also functioning as an APOE4 corrector to enhance its anti-oligomer properties. - The investigational therapy is designed for once-daily dosing with improved gastrointestinal tolerability compared to existing treatments. - Phase 1 results will guide dose selection for future Phase 2 studies in patients with Alzheimer's disease, Down syndrome-associated AD, and cerebral amyloid angiopathy.
- Valiltramiprosate demonstrated significant reductions in plasma p-tau217 levels starting at 26 weeks, with MCI patients showing a 36% decrease compared to 17% increase in placebo group. - Strong correlations were observed between p-tau217 decreases and improvements in cognitive assessments (ADAS-Cog), functional measures (CDR-SB), and hippocampal volume protection. - The Phase 3 APOLLOE4 trial confirmed 94% of APOE4/4 homozygote participants met FDA-approved Alzheimer's disease positivity criteria using plasma biomarker thresholds. - Results validate valiltramiprosate's mechanism of inhibiting neurotoxic soluble amyloid oligomers, positioning it as a potential first-in-class oral disease-modifying therapy for Alzheimer's disease.
- Voyager Therapeutics has launched a new gene therapy program targeting APOE4, the strongest genetic risk factor for Alzheimer's disease, using its proprietary TRACER capsid technology for intravenous delivery. - The bifunctional therapy simultaneously reduces harmful APOE4 expression while delivering protective APOE2 variant, achieving 90% reduction of APOE4 in key brain regions in preclinical studies. - The company's expanded Alzheimer's franchise now includes four wholly-owned assets targeting tau, amyloid, and APOE pathways, with first human data expected in late 2025. - Despite promising preclinical results, the stock has declined 67% year-to-date as investors weigh execution risks against the potential for breakthrough treatment in a market projected to exceed $50 billion by 2030.
- The Alzheimer's drug development landscape has expanded significantly beyond anti-amyloid antibodies, with 88 different clinical trials currently recruiting patients and twelve Phase 3 trials expected to report results in 2025. - Several promising approaches are advancing through late-stage trials, including GLP-1 agonist semaglutide from Novo Nordisk and innovative biologics like vaccines and cell therapies targeting both disease modification and symptom management. - Novel therapeutic modalities are gaining traction, including brain-stimulating devices like Cognito's SPECTRIS headset and magnetic stimulation protocols that showed cognitive benefits in Phase 2 trials.
- Phase 3 APOLLOE4 trial results reveal valiltramiprosate (ALZ-801) demonstrated significant benefits in patients with mild cognitive impairment, showing 52% improvement on ADAS-Cog13 and 102% improvement on CDR-SB scales. - Unlike anti-amyloid monoclonal antibodies, valiltramiprosate showed no increased risk of ARIA compared to placebo, potentially offering a safer treatment option for APOE4 homozygotes who are typically excluded from other therapies. - The oral administration of valiltramiprosate provides a competitive advantage over injectable monoclonal antibodies, with GlobalData forecasting potential US sales of $663.3 million in the MCI population by 2033.
- Alzheon is set to present Phase 3 trial data for ALZ-801 in April 2025, a drug designed to prevent the formation of toxic beta-amyloid plaques in early Alzheimer's patients with the ApoE4 gene. - Anavex Life Sciences has submitted blarcamesine for approval in Europe after completing Phase 2/3 trials, though its efficacy has faced criticism and legal challenges. - Athira Pharma discontinued fosgonimeton development after failing to demonstrate clinical benefit and settled with the DOJ over data manipulation allegations. - Eisai and Biogen's Leqembi may become more accessible with an injectable version under FDA review, potentially allowing for at-home administration.
- Alzheon's ALZ-801 demonstrated a 29% reduction in plasma p-tau181 levels at 26 weeks in patients with early Alzheimer's, indicating a potential disease-modifying effect. - Patients treated with ALZ-801 showed cognitive gains from baseline in memory tests, suggesting improvement rather than just slowing cognitive decline. - The oral agent ALZ-801 exhibited a good safety profile, with no vasogenic edema or drug-related adverse events reported, supporting its tolerability. - A Phase 3 study of ALZ-801 is ongoing in APOE4/4 early AD patients, assessing efficacy, safety, and biomarker effects over a 78-week period.
